• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

作者信息

Breimer D D, Danhof M

机构信息

Leiden/Amsterdam Center for Drug Research, Division of Pharmacology, Leiden University, The Netherlands.

出版信息

Clin Pharmacokinet. 1997 Apr;32(4):259-67. doi: 10.2165/00003088-199732040-00001.

DOI:10.2165/00003088-199732040-00001
PMID:9113436
Abstract
摘要

相似文献

1
Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.药代动力学-药效学建模概念在药物研发中的应用相关性。“木鞋”范式。
Clin Pharmacokinet. 1997 Apr;32(4):259-67. doi: 10.2165/00003088-199732040-00001.
2
Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development.整合而非孤立：为药物发现和开发中的定量和系统药理学辩护。
Drug Discov Today. 2011 Dec;16(23-24):1031-6. doi: 10.1016/j.drudis.2011.10.001. Epub 2011 Oct 13.
3
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.基于机制的药代动力学-药效学建模：生物相分布、受体理论和动力学系统分析。
Annu Rev Pharmacol Toxicol. 2007;47:357-400. doi: 10.1146/annurev.pharmtox.47.120505.105154.
4
An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche.临床药物研发中药代动力学和药效学原理整合的评估。罗氏公司内部经验。
Clin Pharmacokinet. 1997 Aug;33(2):142-52. doi: 10.2165/00003088-199733020-00005.
5
Integrated pharmacokinetics and pharmacodynamics in drug development.药物研发中的整合药代动力学与药效学
Clin Pharmacokinet. 2007;46(9):713-37. doi: 10.2165/00003088-200746090-00001.
6
Modeling promiscuity based on in vitro safety pharmacology profiling data.基于体外安全药理学分析数据对滥交行为进行建模。
ChemMedChem. 2007 Jun;2(6):874-80. doi: 10.1002/cmdc.200700036.
7
Population modelling in drug development.药物研发中的群体建模
Stat Methods Med Res. 1999 Sep;8(3):183-93. doi: 10.1177/096228029900800302.
8
A regulatory perspective on pharmacokinetic/pharmacodynamic modelling.药物代谢动力学/药效学建模的监管视角
Stat Methods Med Res. 1999 Sep;8(3):217-45. doi: 10.1177/096228029900800304.
9
Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.药代动力学和动态推理的早期整合对于先导化合物的优化开发至关重要：战略考量。
Drug Discov Today. 2009 Apr;14(7-8):358-72. doi: 10.1016/j.drudis.2008.12.011. Epub 2009 Jan 20.
10
PK/PD modelling and simulations: utility in drug development.药代动力学/药效学建模与模拟：在药物研发中的应用
Drug Discov Today. 2008 Apr;13(7-8):341-6. doi: 10.1016/j.drudis.2008.01.003. Epub 2008 Mar 7.

引用本文的文献

1
Desorption Electrospray Ionization Mass Spectrometry Imaging Allows Spatial Localization of Changes in Acetaminophen Metabolism in the Liver after Intervention with 4-Methylpyrazole.解吸电喷雾电离质谱成像允许对 4-甲基吡唑干预后肝中对乙酰氨基酚代谢变化进行空间定位。
J Am Soc Mass Spectrom. 2022 Nov 2;33(11):2094-2107. doi: 10.1021/jasms.2c00202. Epub 2022 Oct 12.
2
Dissecting the Pharmacodynamics and Pharmacokinetics of MSCs to Overcome Limitations in Their Clinical Translation.剖析间充质干细胞的药效学和药代动力学以克服其临床转化中的局限性。
Mol Ther Methods Clin Dev. 2019 May 17;14:1-15. doi: 10.1016/j.omtm.2019.05.004. eCollection 2019 Sep 13.
3

本文引用的文献

1
Efficacy measures: surrogates or clinical outcomes?疗效衡量指标：替代指标还是临床结局？
J Clin Pharmacol. 1996 Sep;36(9):767-70. doi: 10.1002/j.1552-4604.1996.tb04249.x.
2
Role of pharmacokinetic-pharmacodynamic principles in rational and cost-effective drug development.药代动力学 - 药效学原理在合理且具成本效益的药物研发中的作用。
Ther Drug Monit. 1996 Aug;18(4):423-8. doi: 10.1097/00007691-199608000-00019.
3
Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers.瑞芬太尼与阿芬太尼：健康成年男性志愿者的药代动力学和药效学比较
Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma.
blinatumomab在非霍奇金淋巴瘤患者中的药代动力学和药效学关系
Curr Clin Pharmacol. 2018;13(1):55-64. doi: 10.2174/1574884713666180518102514.
4
Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects.南非2型糖尿病患者中格列本脲群体药代动力学/药效学建模
Clin Pharmacol. 2016 Sep 26;8:141-153. doi: 10.2147/CPAA.S102674. eCollection 2016.
5
Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models.Sobol 敏感性分析：指导系统药理学模型开发和评估的工具。
CPT Pharmacometrics Syst Pharmacol. 2015 Feb;4(2):69-79. doi: 10.1002/psp4.6.
6
Physiologically Based Absorption Modeling to Design Extended-Release Clinical Products for an Ester Prodrug.基于生理的吸收建模，用于设计酯前药的缓释临床产品。
AAPS J. 2016 Nov;18(6):1424-1438. doi: 10.1208/s12248-016-9950-x. Epub 2016 Jul 12.
7
A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.糖尿病药物研发中新型药物-疾病模型的综合综述
Clin Pharmacokinet. 2016 Jul;55(7):769-788. doi: 10.1007/s40262-015-0359-y.
8
Integration of PKPD relationships into benefit-risk analysis.将药代动力学-药效学关系整合到获益-风险分析中。
Br J Clin Pharmacol. 2015 Nov;80(5):979-91. doi: 10.1111/bcp.12674. Epub 2015 Jul 29.
9
Atazanavir-bilirubin interaction: a pharmacokinetic-pharmacodynamic model.阿扎那韦与胆红素的相互作用：药代动力学-药效学模型
Clin Pharmacol. 2013 Sep 27;5:153-9. doi: 10.2147/CPAA.S48377. eCollection 2013.
10
The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.中枢神经系统药物治疗的策略：人类大脑分布、靶点动力学和治疗效果的转化预测。
Fluids Barriers CNS. 2013 Feb 22;10(1):12. doi: 10.1186/2045-8118-10-12.
Anesthesiology. 1996 Apr;84(4):821-33. doi: 10.1097/00000542-199604000-00009.
4
Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives.临床前研究中的药代动力学-药效学建模：原理与展望。
Eur J Drug Metab Pharmacokinet. 1993 Jan-Mar;18(1):41-7. doi: 10.1007/BF03220007.
5
Comparison of four basic models of indirect pharmacodynamic responses.四种间接药效学反应基本模型的比较。
J Pharmacokinet Biopharm. 1993 Aug;21(4):457-78. doi: 10.1007/BF01061691.
6
Role of patient compliance in clinical pharmacokinetics. A review of recent research.患者依从性在临床药代动力学中的作用。近期研究综述。
Clin Pharmacokinet. 1994 Sep;27(3):202-15. doi: 10.2165/00003088-199427030-00004.
7
Physiologic indirect response models characterize diverse types of pharmacodynamic effects.生理间接反应模型可描述多种类型的药效学效应。
Clin Pharmacol Ther. 1994 Oct;56(4):406-19. doi: 10.1038/clpt.1994.155.
8
Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R- and S-N6-phenylisopropyladenosine in conscious normotensive rats.R-和S-N6-苯基异丙基腺苷对清醒正常血压大鼠心血管作用的药代动力学-药效学建模
J Pharmacol Exp Ther. 1995 Apr;273(1):405-14.
9
Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model.使用非参数药效学模型对药代动力学和药效学进行同步建模。
Clin Pharmacol Ther. 1984 Jun;35(6):733-41. doi: 10.1038/clpt.1984.104.
10
Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin.人体药理效应动力学：华法林的抗凝作用
Clin Pharmacol Ther. 1969 Jan-Feb;10(1):22-35. doi: 10.1002/cpt196910122.